Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,598.00
Bid: 1,601.00
Ask: 1,602.00
Change: -168.50 (-9.54%)
Spread: 1.00 (0.062%)
Open: 1,616.50
High: 1,637.50
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

Wed, 01st May 2024 16:56

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

The FTSE 100 index closed down 22.89 points, 0.3%, at 8,121.24. The FTSE 250 ended down 38.80 points, 0.2%, at 19,926.59, and the AIM All-Share closed up 4.24 points, 0.6%, at 764.98.

The Cboe UK 100 ended down 0.3% at 811.07, the Cboe UK 250 closed down 0.4% at 17,230.04, and the Cboe Small Companies ended up 0.2% at 15,762.48.

Financial markets in Paris and Frankfurt are closed on Wednesday.

The Fed announces its latest interest rate decision at 1900 BST. A press conference with Chair Jerome Powell follows half an hour later.

"It's decision day on interest rates in the US and while the Federal Reserve is almost certain to stick with the status quo, there will be considerable interest in the accompanying commentary. Will markets have to get used to the idea of zero cuts in 2024, having started the year with hopes for rates to be materially lowered?" said AJ Bell's Russ Mould.

Before the Fed decision, there has been a flurry of US data.

The US private sector added more jobs than expected last month, numbers from payroll firm ADP showed.

According to the latest ADP tracker, private employers added 192,000 jobs in April, rising from 184,000 in March. The March reading was downwardly revised from an initially reported 208,000. The latest reading beat the FXStreet cited consensus of 175,000.

The US manufacturing sector was stable in April, purchasing managers' index survey results from S&P Global confirmed on Wednesday, but data from the Institute for Supply Management showed the sector fell into contraction.

The S&P Global US manufacturing PMI posted in line with the 50.0 no-change mark in April to point to stable business conditions at the start of the second quarter. The reading was down from 51.9 in March and signalled an end to a three-month sequence of improving operating conditions.

The ISM PMI reported that economic activity in the manufacturing sector contracted in April after one month of expansion following 16 consecutive months of contraction.

The ISM PMI for manufacturing reading slipped to 49.2 points in April from 50.3 in March.

Stocks in New York were mixed at the London equities close. The DJIA was up 0.2%, though the S&P 500 index and Nasdaq Composite were down 0.4% and 0.5%, respectively.

The pound was quoted at USD1.2487 at the London equities close Wednesday, down compared to USD1.2523 at the close on Tuesday. The euro stood at USD1.0679 at the European equities close Wednesday, lower against USD1.0690 at the same time on Tuesday.

Against the yen, the dollar was trading at JPY157.72, up compared to JPY157.44 late Tuesday.

In the FTSE 100, Haleon lost 3.1%.

The Surrey, England-based consumer health arm, spun out of GSK PLC, backed its annual guidance and reported a "solid" quarter.

Revenue declined 2.2% on-year to GBP2.92 billion in the three months that ended March 31, as revenue for Haleon's Pain Relief and Respiratory Health units fell amid a weaker Covid season in China compared to a year ago.

Cost of sales were reduced by 5.7% to GBP1.08 billion from GBP1.15 billion, helping pretax profit to grow by 8.9% to GBP590 million from GBP542 million.

On the other hand, GSK rose 1.6%.

The London-based pharmaceutical maker said revenue in the first-quarter of the year was up 5.9% to GBP7.36 billion from GBP6.95 billion a year prior.

Pretax profit, however, weakened 29% to GBP1.36 billion from GBP1.91 billion.

In the FTSE 250, Aston Martin lost 6.8%, after a disappointing trading update.

The company reported 945 vehicle sales in the first quarter, down 26% from 1,269 a year before.

Pretax loss widened 87% to GBP138.8 million from GBP74.2 million.

Executive Chair Lawrence Stroll said: "2024 is a year of immense product transformation at Aston Martin, with the introduction of four new models to the market before the end of the year. Our first quarter performance reflects this expected period of transition, as we ceased production and delivery of our outgoing core models ahead of the ramp up in production of the new Vantage, upgraded DBX707 and our upcoming V12 flagship sports car which we've confirmed today. As part of our ongoing programme of ultra-exclusive models, we will deliver a new Special in the fourth quarter of the year."

On AIM, Trinity Exploration & Production rose 53%. Touchstone Exploration shares fell 4.5%.

Touchstone Exploration said it reached an agreement to buy Trinity Exploration & Production.

The Trinidad & Tobago-focused oil exploration and production companies aim to become "a leading Trinidadian operator of scale," according to Touchstone, which calls itself the largest independent onshore oil and natural gas producer in Trinidad.

The all-share agreement values Trinity at GBP24.1 million.

Brent oil was quoted at USD83.78 a barrel at the London equities close Wednesday, down from USD86.42 late Tuesday.

Gold was quoted at USD2,308.30 an ounce at the London equities close Wednesday, up against USD2,298.10 at the close on Tuesday.

In Thursday's UK corporate calendar, has first quarter results from Endeavour Mining, Shell, and Standard Chartered.

The economic calendar for Thursday has manufacturing PMIs from Germany and the eurozone. At 1330 BST, there is the weekly US initial jobless claims, as well as trade balance data.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.